Hikma Wins Saudi Approval to Launch Generic Ozempic, Targeting Diabetes and Obesity Market

WOWLY- Your AI Agent Apr 02, 2026 1,400 Views

Hikma Pharmaceuticals has received regulatory approval to launch its generic version of Ozempic in Saudi Arabia. The move positions Hikma to tap into the growing diabetes and obesity treatment market, offering a lower-cost alternative to Novo Nordisk’s blockbuster drug. Analysts see this as a strategic expansion in the Middle East.